Extraordinary General Meeting

Please click on the links below for information concerning Genmab A/S’ Extraordinary General Meeting 2026.

• Notice of Extraordinary General Meeting 2026 with agenda, including Appendix 1: Shareholder Letter
• Register online or use the registration form
• Submit proxy or postal vote online or use the form to submit proxy or postal vote

Elizabeth O’Farrell, Chair of the Compensation Committee, provides additional context on the Board of Directors’ 2026 remuneration proposal and the shareholder feedback that informed it.

Selected materials from Genmab’s shareholder outreach are also available below.

• Genmab Investor Outreach - Discussion Materials

For additional information on Genmab A/S’ remuneration framework and the remuneration awarded to the Board of Directors, please see:

• Remuneration Policy
• 2025 Compensation Report

The total number of voting rights and total share capital per September 8, 2026, is:
Total Number of Voting Rights: 62,377,844
Total Share Capital: 62,377,844

Questions regarding registration to participate may be directed to Euronext Securities at tel. no. (+45) 43 58 88 66 or CPH-investor@euronext.com.

We process your personal data in accordance with applicable rules. Please click here to read our Privacy Policy.

Please note that Genmab A/S, as a general rule, no longer sends notices convening General Meetings by postal mail. If you wish to receive notices of future General Meetings via e-mail, please register your e-mail address at the InvestorPortal. If you do not have access to an e-mail address, please contact Euronext Securities at: +45 4358 8866.